Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.37 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234583 | 0.82 | DPP7 (0.48) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL6234578 | 0.82 | DPP7 (0.48) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL6234680 | 0.78 | DPP7 (0.42) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL6234685 | 0.78 | DPP7 (0.42) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL29223958 | 0.73 | ACE (0.50) | ACECPB2FOLH1ITGB3ITGA2B | |
| SCHEMBL29223957 | 0.73 | ACE (0.50) | ACECPB2FOLH1ITGB3ITGA2B | |
| SCHEMBL29223959 | 0.73 | ACE (0.50) | ACECPB2FOLH1ITGB3ITGA2B | |
| SCHEMBL48406 | 0.70 | FOLH1 (0.58) | CPB2FOLH1GSRRNPEP | |
| SCHEMBL1054672 | 0.70 | FOLH1 (0.58) | CPB2FOLH1GSRRNPEP | |
| SCHEMBL48407 | 0.70 | FOLH1 (0.58) | CPB2FOLH1GSRRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927290-B2 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1160236-B1 | Production of mixed acid anhydride and amine compound | SUMITOMO CHEMICAL CO (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20040210059-A1 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-10-21 | — | — | US | disclosed |
| US-6753431-B2 | REACTING A CARBAMATE DERIVATIVE WITH CARBOXYLIC AND HALOFORMIC ACID DERIVATIVES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20020032346-A1 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL CO., LTD. | 2002-03-14 | — | — | US | disclosed |
| EP-1160236-A2 | Production of mixed acid anhydride and amine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210059-A1 | Production of mixed acid anhydride and amide compound | CA2, CA1, CA3 | ACE 2592/4885CPB2 751/4885DPP7 4184/4885 |
| US-20020032346-A1 | Production of mixed acid anhydride and amide compound | CA2, CA1, CA3 | ACE 2592/4885CPB2 751/4885DPP7 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.